Financial & competing interest disclosure
The authors acknowledge financial support from the Dutch Cancer Society KWF-Alpe d’HuZes grant no. 13058 and grant no. 8025. A Kubiak was employed by Exomnis Biotech BV until 2022. LJD has, outside of the submitted work, minority shares in Convert Pharmaceuticals and LivingMed Biotech. JT has, outside of the submitted work, minority shares in Convert Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.